Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XII.ai

Cardiotoxicity

A broad term often representing life-threatening scenarios including myocarditis, dysrhythmias, ventricular tachycardia, conduction abnormalities, heart failure, and/or valvular heart disease (PMID 29912044, 29980467)

Publications

Xavier CB, Lopes CDH, Harada G, Peres EDB, Katz A, Jardim DL

Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis.

Translational oncology. 2022;19:101383

Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, Roden DM, Johnson DB, Moslehi JJ

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.

The Lancet. Oncology. 2018;19(12):1579-1589

Mir H, Alhussein M, Alrashidi S, Alzayer H, Alshatti A, Valettas N, Mukherjee SD, Nair V, Leong DP

Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area.

The Canadian journal of cardiology. 2018;34(8):1059-1068

Asnani A

Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management.

Current oncology reports. 2018;20(6):44

Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, Luke JJ

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.

Journal for immunotherapy of cancer. 2016;4:50